Comparison of NMTCuff and Standard TOF in Gynecologic Oncology Surgery (NMTCUFF-TOF)

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Observational

Phase

Not applicable / not listed

Age range

18 years - 75 years

Sex eligible

Female

Healthy volunteers

Not accepted

Participants

45 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The use of neuromuscular blocking (NMB) agents in modern anesthesia is essential for optimizing surgical exposure and ensuring patient safety. Inadequate neuromuscular recovery at the end of surgery, known as residual curarization, poses significant risks for critical postoperative respiratory complications, aspiration pneumonia, and prolonged recovery times. Therefore, objective neuromuscular monitoring is strongly recommended by international guidelines, including the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC).

In gynecologic oncology surgery, laparoscopic and robotic approaches often require deep neuromuscular blockade (Post-Tetany Count 1-2) to improve abdominal exposure and allow surgeons to work at lower intraperitoneal pressures. However, the extreme Trendelenburg position and the "tucked-in" positioning of the arms under surgical drapes limit the feasibility of traditional acceleromyography (AMG) monitoring methods. Since AMG devices require free movement of the thumb (m. adductor pollicis), they can yield false-positive or unreliable results when the arms are inaccessible, forcing clinicians to rely on subjective monitoring.

The NMTCuff technology, used by the Vision Duo monitor, measures the neuromuscular response via the contraction pressure of the upper arm muscles (m. triceps/biceps brachii) rather than the wrist. Literature indicates that the response of upper arm muscles correlates better with the diaphragm and laryngeal muscles regarding NMB sensitivity compared to the wrist. This feature suggests that the Vision Duo might detect the recovery of respiratory functions earlier and more reliably.

This study aims to evaluate the correlation and time differences in Train-of-Four (TOF) ratios between the NMTCuff and standard AMG methods during gynecologic oncology surgery. Additionally, it will assess the ease of setup and signal continuity of both devices when the patient's arms remain covered under surgical drapes.

This study is purely prospective and observational in terms of clinical management. The neuromuscular monitoring methods used will not interfere with routine anesthesia care, drug dosing, muscle relaxant reversal strategies, or extubation decisions. The clinician performing the anesthesia management will follow the institutional routine protocol, and data from both devices will only be recorded simultaneously and matched for statistical comparison.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Female patients scheduled for elective laparoscopic gynecologic oncology surgery
• Aged between 18 and 75 years
• American Society of Anesthesiologists (ASA) physical status I-III
• Patients who provide written and verbal informed consent

Exclusion Criteria:

• Known history of neuromuscular disease
• Severe hepatic or renal insufficiency
• Body Mass Index (BMI) greater than 35 kg/m2
• Patient refusal to participate

Study population

Female patients aged 18-75 years with an ASA status of I-III who are scheduled to undergo elective laparoscopic gynecologic oncology surgery at Dr. Abdurrahman Yurtarslan Oncology Training and Research Hospital.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not reported

Masking

Not reported

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Study start

Sep 1, 2026 Actual

Primary completion

Nov 1, 2026 Actual

Study completion

Nov 30, 2026 Estimated

First posted

Nov 9, 2026 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts